What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: GlobalData | PRODUCT CODE: 1097806

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 1097806

Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

PAGES: 58 Pages
DELIVERY TIME: 1-2 business days
PDF (Single User License)
USD 3495
PDF (Site License)
USD 6990
PDF (Global License)
USD 10485

Add to Cart

This reports provides a data-driven overview of the current and future competitive landscape in Alport Syndrome therapeutics.


  • In 2022, diagnosed prevalence of Alport syndrome will reach to 359,000 cases across the 16 countries covered in GlobalData's epidemiology forecast.
  • There are no approved marketed products for the treatment of Alport syndrome.
  • R&D activity in Alport syndrome is limited, with only one product in late-stage development.
  • Reata pharmaceuticals dominate clinical trial development in Alport syndrome, with the US emerging as the key countries for conducting trials in Alport syndrome.
  • No deal activity observed within the Alport syndrome space during the past 24 months.
  • Therapeutic options for Alport syndrome patients continue to be limited, with only one therapy reaching the market during next 18 months.


GlobalData's Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Alport Syndrome market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alport Syndrome market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Product Code: GDHC063CL

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs

5 Pipeline Drugs Assessment

  • 5.1 Phase III Pipeline Drugs
  • 5.2 Overview by Development Stage
  • 5.3 Overview by Molecule Type
  • 5.4 Overview by Mechanism of Action
  • 5.5 Overview by Route of Administration
  • 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6 Clinical Trials Assessment

  • 6.1 Historical Overview
  • 6.2 Overview by Phase
  • 6.3 Overview by Status
  • 6.4 Overview by Phase for Ongoing and Planned Trials
  • 6.5 Trials with Virtual Components
  • 6.6 Geographic Overview
  • 6.7 Single-Country and Multinational Trials by Region
  • 6.8 Top 20 Sponsors with Breakdown by Phase
  • 6.9 Top 20 Sponsors with Breakdown by Status
  • 6.10 Overview by Endpoint Status
  • 6.11 Overview by Race and Ethnicity
  • 6.12 Enrollment Data
  • 6.13 Top 20 countries for Trial Sites
  • 6.14 Top 20 Sites Globally
  • 6.15 Feasibility Analysis - Geographic Overview
  • 6.16 Feasibility Analysis - Benchmark Models

7 Deals Landscape

  • 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

  • 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

  • 10.1 Methodology
  • 10.2 Methodology - PTSR and LoA Analysis
  • 10.3 About the Authors
  • 10.4 Contact Us
  • 10.5 Disclaimer
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!